Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case–control analyses from UK primary care

• Luis Alberto García Rodríguez,
• Pareen Vora,
• Luke Roberts,
• Gunnar Brobert,
• Samuel Fatoba,
• María Eugenia Sáez,
• Antonio González-Pérez

Affiliations

Luis Alberto García Rodríguez

1 Pharmacoepidemiology, Spanish Centre for Pharmacoepidemiological Research, Madrid, Spain

Pareen Vora

Epidemiology, Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany

Luke Roberts

4 Study Medical Experts, Bayer plc, Reading, UK

Gunnar Brobert

3 Epidemiology, Bayer AB, Stockholm, Sweden

Samuel Fatoba

5 Medical Affairs, Bayer plc, Reading, UK

María Eugenia Sáez

Aff2 Centro Andaluz de Estudios Bioinformáticos (CAEBi) Seville Spain

Antonio González-Pérez

Aff2 Centro Andaluz de Estudios Bioinformáticos (CAEBi) Seville Spain